Dr. Matthew Cooperberg on the Effectiveness of Active Surveillance in Prostate Cancer
Cooperberg says the likelihood of a patient for staying on active surveillance for 10 or 15 years is around 50%, though men who stay on active surveillance for between 6 months and 5 years generally see progression in their disease.
Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco (UCSF), discusses the effectiveness of active surveillance in prostate cancer. Cooperberg says the likelihood of a patient for staying on active surveillance for 10 or 15 years is around 50%, though men who stay on active surveillance for between 6 months and 5 years generally see progression in their disease.
Recent Videos
Related Content
